» Articles » PMID: 32489221

Case-only Trees and Random Forests for Exploring Genotype-specific Treatment Effects in Randomized Clinical Trials with Dichotomous Endpoints

Overview
Specialty Public Health
Date 2020 Jun 4
PMID 32489221
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Discovering gene-treatment interactions in clinical trials is of rising interest in the era of precision medicine. Nonparametric statistical learning methods such as trees and random forests are useful tools for building prediction rules. In this article, we introduce trees and random forests to the recently proposed case-only approach for discovering gene-treatment interactions and estimating marker-specific treatment effects for a dichotomous trial endpoints. The motivational example is a case-control genetic association study in the Prostate Cancer Prevention Trial (PCPT), which tested the hypothesis whether finasteride can prevent prostate cancer. We compare this novel approach to the interaction tree method previously proposed. Because of the modeling simplicity - directly targeting at interaction - and the statistical efficiency of the case-only approach, case-only trees and random forests yield more accurate prediction of heterogeneous treatment effects and better measure of variable importance, relative to the interaction tree method which uses data from both cases and controls. Application of the proposed case-only trees and random forests to the PCPT study yielded a discovery of genotypes that may influence the prevention effect of finasteride.

Citing Articles

Causal inference methods for vaccine sieve analysis with effect modification.

Yang G, Balzer L, Benkeser D Stat Med. 2022; 41(8):1513-1524.

PMID: 35044691 PMC: 10517342. DOI: 10.1002/sim.9302.


Quantitative prediction model for affinity of drug-target interactions based on molecular vibrations and overall system of ligand-receptor.

Wang X, Cao T, Jia C, Tian X, Wang Y BMC Bioinformatics. 2021; 22(1):497.

PMID: 34649499 PMC: 8515642. DOI: 10.1186/s12859-021-04389-w.

References
1.
Goodman P, Tangen C, Kristal A, Thompson I, Lucia M, Platz E . Transition of a clinical trial into translational research: the prostate cancer prevention trial experience. Cancer Prev Res (Phila). 2010; 3(12):1523-33. PMC: 3058741. DOI: 10.1158/1940-6207.CAPR-09-0256. View

2.
Lagakos S . The challenge of subgroup analyses--reporting without distorting. N Engl J Med. 2006; 354(16):1667-9. DOI: 10.1056/NEJMp068070. View

3.
Assmann S, Pocock S, Enos L, Kasten L . Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet. 2000; 355(9209):1064-9. DOI: 10.1016/S0140-6736(00)02039-0. View

4.
Dai J, Zhang X, Wang C, Kooperberg C . Augmented case-only designs for randomized clinical trials with failure time endpoints. Biometrics. 2015; 72(1):30-8. PMC: 4808468. DOI: 10.1111/biom.12392. View

5.
Piegorsch W, Weinberg C, Taylor J . Non-hierarchical logistic models and case-only designs for assessing susceptibility in population-based case-control studies. Stat Med. 1994; 13(2):153-62. DOI: 10.1002/sim.4780130206. View